- Home
- Publications
- Publication Search
- Publication Details
Title
AR Splicing Variants and Resistance to AR Targeting Agents
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 11, Pages 2563
Publisher
MDPI AG
Online
2021-05-24
DOI
10.3390/cancers13112563
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells
- (2021) Wenting Pan et al. CLINICAL CANCER RESEARCH
- Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
- (2021) M. Del Re et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Targeting p300/CBP axis in lethal prostate cancer
- (2021) Jonathan Welti et al. Cancer Discovery
- TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
- (2021) Samuel R. Denmeade et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer.
- (2021) Ronan Le Moigne et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial
- (2021) Eugene Shenderov et al. PROSTATE
- A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
- (2021) Yundong He et al. Nature Communications
- Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
- (2021) Mamta Parikh et al. Scientific Reports
- A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
- (2020) David Johnson Einstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer
- (2020) Mark C. Markowski et al. PROSTATE
- Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
- (2020) Changxue Lu et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?
- (2020) Mayuko Kanayama et al. EUROPEAN UROLOGY
- Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
- (2020) Heidi Fettke et al. EUROPEAN UROLOGY
- Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
- (2020) Christos E. Kyriakopoulos et al. CLINICAL CANCER RESEARCH
- A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer
- (2020) Rahul R. Aggarwal et al. CLINICAL CANCER RESEARCH
- A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts
- (2020) Mark C. Markowski et al. EUROPEAN UROLOGY
- Identification of long non-coding RNAs in advanced prostate cancer associated with androgen receptor splicing factors
- (2020) Ken-ichi Takayama et al. Communications Biology
- First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
- (2020) Malaka Ameratunga et al. BRITISH JOURNAL OF CANCER
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- (2020) Padmanee Sharma et al. CANCER CELL
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
- (2019) Adam Sharp et al. EUROPEAN UROLOGY
- An open label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumors.
- (2019) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer
- (2019) Claire E. Fletcher et al. ONCOGENE
- SF3B2-mediated RNA splicing drives human prostate cancer progression
- (2019) Norihiko Kawamura et al. CANCER RESEARCH
- The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
- (2019) Yuqian Yan et al. EMBO Molecular Medicine
- Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer
- (2019) Mary-Ellen Taplin et al. EUROPEAN UROLOGY
- Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage
- (2019) Payel Chatterjee et al. JOURNAL OF CLINICAL INVESTIGATION
- Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer
- (2018) Yezi Zhu et al. EUROPEAN UROLOGY
- A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.
- (2018) Ulka N. Vaishampayan et al. JOURNAL OF CLINICAL ONCOLOGY
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
- (2018) Willi Sauerbrei et al. JNCI-Journal of the National Cancer Institute
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
- (2018) Michael T. Schweizer et al. PLoS One
- Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
- (2018) Zhong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy
- (2018) Xin Chen et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells
- (2018) Marie C. Hupe et al. WORLD JOURNAL OF UROLOGY
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
- (2018) Karim Boudadi et al. Oncotarget
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
- (2018) Willi Sauerbrei et al. JNCI-Journal of the National Cancer Institute
- Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
- (2018) Howard I. Scher et al. JAMA Oncology
- Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
- (2018) Adam Sharp et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns
- (2017) Bram De Laere et al. EUROPEAN UROLOGY
- The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients
- (2017) Marzia Del Re et al. EUROPEAN UROLOGY
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
- (2017) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF
- (2017) Ken-ichi Takayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emerging Variants of Castration-Resistant Prostate Cancer
- (2017) Panagiotis J. Vlachostergios et al. Current Oncology Reports
- Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells
- (2017) Brian M. Olson et al. Cancer Immunology Research
- Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
- (2017) Naoki Terada et al. Therapeutic Advances in Medical Oncology
- ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of patients with castration resistant prostate cancer
- (2016) M. Björkman et al. EUROPEAN JOURNAL OF CANCER
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
- (2016) Emily J. Faivre et al. MOLECULAR CANCER RESEARCH
- Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance
- (2016) Yang Zhan et al. MOLECULAR CANCER RESEARCH
- Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
- (2016) E. S. Antonarakis et al. ONCOLOGIST
- Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
- (2016) Christine Henzler et al. Nature Communications
- Regulation of androgen receptor splice variant AR3 by PCGEM1
- (2016) Ziqiang Zhang et al. Oncotarget
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2016) Alexander W. Wyatt et al. JAMA Oncology
- Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
- (2015) D. Xu et al. CANCER RESEARCH
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
- (2015) Y. Yang et al. CLINICAL CANCER RESEARCH
- Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
- (2015) Eleni Efstathiou et al. EUROPEAN UROLOGY
- Biomarker: Predictive or Prognostic?
- (2015) Karla V. Ballman JOURNAL OF CLINICAL ONCOLOGY
- RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
- (2015) D. T. Miyamoto et al. SCIENCE
- The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7
- (2015) Jacqueline Stockley et al. Scientific Reports
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
- (2015) Bo Cao et al. Oncotarget
- Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer
- (2014) Z. Zhang et al. CANCER RESEARCH
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Mechanisms of the androgen receptor splicing in prostate cancer cells
- (2013) L L Liu et al. ONCOGENE
- TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
- (2013) M. D. Nyquist et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal
- (2012) Siu Chiu Chan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
- (2012) Y Li et al. ONCOGENE
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
- (2011) Changmeng Cai et al. CANCER CELL
- Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
- (2011) Y. Li et al. CANCER RESEARCH
- Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
- (2011) Emma Hörnberg et al. PLoS One
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
- (2010) Klaus Strebhardt NATURE REVIEWS DRUG DISCOVERY
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Minireview: The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling
- (2008) Margaret M. Centenera et al. MOLECULAR ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search